Editor Notes: We sold out on ANTB. Despite the promising outlook of the firm, it is highly unlikely to work without significant side effect based on our molecule analysis. However, the firm might add new molecule to deepen the pipeline and we might make our purchase recommendation. As for now, we recommend a sell.
Global market for Type 1 and 2 diabetes is more than $11 billion.
Antria lead molecule ABI-101 can disrupt this market due to its once weekly convenient dosing schedule.
Early preclinical data based on molecule analysis shows promising results in both efficacy and safety for the small cap biopharma with mammoth upsides.
The management has extensive experience, strong pedigrees and market wisdom to be highly likely to cut into a vast market.
AntriaBio (OTC:ANTB) is a small biopharmaceutical company—headquartered in Louisville Colorado and is innovating lifesaving diabetes treatment far advanced of competitors—that recently released promising preclinical data for lead drug ABI-101.